Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Int J Colorectal Dis ; 39(1): 60, 2024 Apr 27.
Article in English | MEDLINE | ID: mdl-38676763

ABSTRACT

INTRODUCTION: The pleiotropic effects of statins have attracted considerable attention in oncological treatment. Several preclinical and epidemiological studies have highlighted their potential anti-tumor properties in patients with colorectal cancer, although results have been conflicting. This study aimed to examine the association between statin exposure before colorectal cancer surgery with long and short-term survival outcomes. METHODS: This retrospective propensity score-adjusted study was conducted on a Danish cohort of patients who underwent elective curative-intended surgery for stage I-III colorectal cancer in 2008-2020, using four national patient databases. The primary and secondary outcomes were overall, 90-day, and disease-free survival. Propensity scores were calculated using all available data to match patients with and without statin exposure in a 1:1 ratio. RESULTS: Following propensity score matching, 7120 patients were included in the primary analysis. The median follow-up time was 5 years. A Cox proportional hazards model showed no statistically significant difference in overall survival between patients with or without statin exposure 365 days before surgery (HR 0.93, 95% CI 0.85-1.02) and no association with 90-day survival (OR 0.91, 95% CI 0.76-1.10). However, a subgroup analysis examining a 90-day exposure before surgery found a statistically significant association with increased overall survival (HR 0.85, 95% CI 0.77-0.93). CONCLUSION: Although a subgroup of patients with a preoperative exposure time of 90 days showed statistically significant better overall survival, we found no statistically significant association between statin exposure 1 year before colorectal cancer surgery and overall survival.


Subject(s)
Colorectal Neoplasms , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Propensity Score , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Colorectal Neoplasms/surgery , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Male , Female , Aged , Middle Aged , Preoperative Care , Time Factors , Retrospective Studies , Denmark/epidemiology , Disease-Free Survival , Treatment Outcome , Cohort Studies
2.
HNO ; 72(5): 377-388, 2024 May.
Article in German | MEDLINE | ID: mdl-38536466

ABSTRACT

Recording of vestibular evoked myogenic potentials (VEMPs) is a well-established method for functional diagnostics of the otolith organs. VEMPs are vestibular reflexes of the sacculus und utriculus to acoustic stimulation by air-conducted sound or bone-conducted vibration and are recorded by surface electrodes from the cervical (cVEMP) and ocular (oVEMP) muscles. The results of VEMP recordings are part of the neuro-otologic test battery and enable diagnosis of various vestibular disorders or differentiation between non-vestibular and peripheral vestibular vertigo. However, the methods for recording VEMPs vary substantially, although recording and stimulation parameters as well as methods of data analysis have a significant influence on the results. This article provides an overview of recommended parameters as well as practical instructions for the recording, analysis, and interpretation of VEMPs.


Subject(s)
Vestibular Evoked Myogenic Potentials , Humans , Vestibular Evoked Myogenic Potentials/physiology , Electromyography/methods , Practice Guidelines as Topic , Vestibular Diseases/diagnosis , Vestibular Diseases/physiopathology , Vestibular Function Tests/methods
3.
Ugeskr Laeger ; 185(34)2023 08 21.
Article in Danish | MEDLINE | ID: mdl-37622604

ABSTRACT

Interactions in the tumour microenvironment (TME) are complex and pose a major oncological challenge. Immunotherapy has led to significant progress in recent years, however, not all patients benefit from this. An increasing number of trials try to modulate the TME. Interferon type I (IFN-I) proteins play an important role in the immune response, having many beneficial effects in patients with cancer, particularly when administered locally. This review finds that targeted intratumoural delivery of IFN-I to the TME may mediate optimal therapeutic effects in solid cancers, having extensive implications for clinical oncology. However, an increased understanding of the mechanisms is imperative to develop new and better treatments for solid cancers.


Subject(s)
Interferon Type I , Neoplasms , Humans , Neoplasms/therapy , Medical Oncology , Immunotherapy , Tumor Microenvironment
SELECTION OF CITATIONS
SEARCH DETAIL
...